09.00 Pharma IQ’s And Chair’s Welcome

Chairperson:

William E. Solander
Partner
Fitzpatrick, Cella, Harper & Scinto

09.15 Opening Keynote: International IP

• Assessment of the current International IP environment
• Potential problems in designing and implementing your IP policy
• Political problems within the area of IP and potential developments within the next year

Bo Hammer Janssen
Senior Patent Counsel
Novozymes

10.00 Maximising Crystalline Form And Polymorph Patent Wealth: European Perspective

• Which properties / data can be generated while patenting polymorphic forms?
• Drafting applications on polymorphs for EU
• Prosecuting patent applications on polymorphs in the EU
• How to prove infringement of polymorph patents
• Avoiding infringements, i.e. design around, of polymorph patents
• Key factors to be considered while considering filing a suit on polymorph patents. For example, raw data, formulation data, expert testimony etc.

James Horgan
Assistant Counsel, Merck
Sharpe & Dohme Ltd

11.15 Analysing The Utility Of Your Patent

• Pros and cons of evergreening / brand extensions through patents
• Strategic considerations for licensing of polymorph patents
• Understanding the enforceability of polymorph patents
• Preparing for due diligence and risk analysis

Dr Mandar Kodgule
Head, Intellectual Property & Strategic Planning
Wockhardt Ltd

12.00 Scientist Perspective: Strategy For First Time Patent Approval

• How much data do you need to support your claim?
• Advantages of using new technology to support your patent vs. old technology
• Internal strategy to ensure first time patent approval

Dr William Heggie
CSO
Hovione

14.00 Formulating A Robust Blueprint Strategy For Patent Applications

• Step by step guide to designing the strategy
• Common objections and pitfalls
• Implementing the best practice policy

Nicolas Ruiz
Head of IP
Esteve

14.45 European Patent Office: Filing And Approval And How Applications Have Changed In The Last 12 Months

• How patentability of a crystalline form is approached in the EPO
• Recent European case law relating to solid state and connected fields
• Precautions to take when drafting and description within claims
• How much data is required? Is there such a thing as too much?

Dr Thomas Weisbrod
Patent Examiner
European Patent Office

16.00 The Glivec Polymorph Case In India: History And Current Status

• Deficiencies and shortcomings of Section 3(d)
• The impact of Section 3(d) on the patentability of new crystal forms
• The history of the conflict concerning Glivec in India
• From the High Court to the IP Appellate Board and Beyond

Peter Roth
Senior Patent Counsel
Novartis

16.45 Ensuring Effective Lifecycle Management Of Your Patent

• Effectively analysing when to patent your product
• Assessing different forms for continued patent coverage
• Maximising the revenue of your patent
• Balancing timing and scope in your filing strategy
• Implementing a lifecycle management plan in the current legal and regulatory climate

Lisa Dixon
Senior Patent Counsel
Vertex

17.30 Chair’s Closing Remarks

17.45 Close Of Conference Day One